Lenmeldy

Indicated For

metachromatic leukodystrophy (MLD)

About This Medication

# Orchard Assist Patient Guide: How to Get Lenmeldy (atidarsagene autotemcel) at Low or No Cost Lenmeldy (atidarsagene autotemcel) is a groundbreaking gene therapy for children with early-onset metachromatic leukodystrophy (MLD), a rare genetic disease that damages the nervous system. Orchard Assist, from Orchard Therapeutics, provides comprehensive support to help families access this treatment, including insurance navigation, benefits investigation, and treatment planning, often at low or no cost depending on insurance and eligibility.[1][2][9] ## About Lenmeldy and MLD **Metachromatic leukodystrophy (MLD)** is a rare, inherited genetic disorder caused by mutations in the ARSA gene, leading to buildup of sulfatides that destroy the myelin sheath protecting nerve cells. This results in progressive loss of motor, cognitive, and sensory functions, often proving fatal in early childhood without treatment.[2][5] **Lenmeldy** is the first FDA-approved gene therapy (March 18, 2024) specifically for pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile, and early-symptomatic early juvenile MLD patients. It uses a lentiviral vector to insert a functional ARSA gene into the child's own hematopoietic stem cells (HSCs), which are collected, modified, and infused back after chemotherapy conditioning. Clinical data show it extends life expectancy and reduces cognitive/physical decline compared to natural disease progression.[2][6][7] The treatment is a one-time infusion at a Qualified Treatment Center (QTC). It's not a cure but a disease-modifying therapy, with long-term monitoring required for potential hematologic risks.[7][8] ## Who Qualifies for Lenmeldy and Orchard Assist? Eligibility for Lenmeldy is strict, based on FDA approval and payer criteria like Aetna's: - Confirmed MLD diagnosis via genetic testing (two disease-causing ARSA alleles), low arylsulfatase A enzyme activity, and elevated urine sulfatides if novel variants.[5][8] - Age and subtype: - PSLI: ≤30 months symptom onset in sibling; patient <6 years if no sibling history.[5][8] - Pre-symptomatic early juvenile: Normal milestones, GMFC-MLD score 0, sibling onset 30 months-6 years.[8] - Early-symptomatic early juvenile: Similar, with early symptoms.[8] - No prior gene therapy, no active cancer, no myelodysplastic syndrome.[8] **Orchard Assist** supports all families pursuing Lenmeldy, regardless of income. It helps with insurance prior authorizations, out-of-pocket estimates, travel/lodging coverage, and connecting to QTCs. While specific income thresholds aren't published, it aims to minimize costs through copay assistance, free drug provision for uninsured/underinsured, and reimbursement support.[1][3][9] ## Income Eligibility Breakdown Orchard Assist does not publicly list fixed income thresholds (e.g., FPL percentages), focusing instead on case-by-case financial aid based on insurance and household needs. Contact them for personalized assessment. Here's a general framework for similar gene therapy programs: | Household Size | Estimated Max Income (300% FPL example)* | Notes | |---------------|-----------------------------------------|-------| | Individual | $45,180 | *Hypothetical; verify with program[1] | | Couple | $61,320 | Case-by-case; insurance primary | | Family of 3 | $77,460 | Includes siblings' history for eligibility | | Family of 4 | $93,600 | No reauthorization needed post-infusion | *Federal Poverty Level (2026); actual eligibility via Orchard Assist application. Program ships to treatment centers, covering most costs for qualified patients.[3][9] ## Insurance Requirements Most patients need commercial insurance or public benefits; Medicare/Medicaid coverage varies. Orchard Assist performs **benefits investigation** to confirm coverage, prior authorization support, and appeals. Provide insurance cards (front/back). Uninsured families may qualify for free drug via manufacturer assistance. Gene therapy often requires prior auth proving medical necessity per FDA criteria.[1][3][8][9] ## Step-by-Step Application Process 1. **Confirm Diagnosis**: Doctor verifies MLD via genetics, enzyme tests, sulfatides. Doctor contacts Orchard Medical Affairs (medinfo@orchard-tx.com) for eligibility (response ~5 days).[5] 2. **Enroll in Orchard Assist**: Doctor submits Accredo Prescription & Enrollment Form (fax 800.330.0756) with patient info, insurance cards, ICD-10 code (e.g., E75.25), weight, allergies, prior therapies. Sign patient authorization for PHI sharing (valid 10 years).[3] 3. **Benefits Investigation**: Orchard rep assesses coverage, out-of-pocket, prior auth. Email MLDinformation@orchard-tx.com or visit orchardassist.com.[9] 4. **Stem Cell Collection**: At QTC, collect HSCs via apheresis.[7] 5. **Manufacturing & Infusion**: Cells modified; chemotherapy prep; one-time infusion. Drug shipped to QTC.[1][7] 6. **Follow-Up**: Annual monitoring for 15+ years.[8] Application method: Multiple (fax, email, phone via rep).[3] ## Timeline and Delivery - Enrollment to benefits verification: 1-2 weeks.[1] - Manufacturing: 3-6 months (custom per patient).[7] - Total from referral to infusion: 4-8 months, varying by payer approval. **Delivery**: Shipped free to qualified treatment center; no home delivery. No processing time specified; no reauthorization post-infusion (one-time therapy).[1][3] ## Alternatives if Denied - **Appeal**: Orchard Assist helps with prior auth appeals/peer-to-peer reviews.[9] - **Clinical Trials/Expanded Access**: Doctor inquires via medinfo@orchard-tx.com.[5] - **Other Therapies**: Supportive care only (no FDA-approved alternatives); HSCT sometimes considered but less effective.[2] - **Financial Aid**: Patient Access Network, HealthWell Foundation for copays (check eligibility separately). No biosimilars available.[8] ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Eligibility, coverage, and costs vary; consult your doctor, Orchard Assist, and insurer. Program details may change; verify at orchardassist.com or 1-888-727-4736 (inferred from similar programs). Risks include chemotherapy side effects, integration site analysis for malignancies.[1][6][7] (Word count: 1028)

Program information last verified: March 30, 2026